Prelude Therapeutics Inc. (PRLD) announced on Friday new clinical data from its ongoing Phase 1 trial of PRT3789, a pioneering SMARCA2 degrader aimed at treating cancer patients with a SMARCA4 mutation.The preliminary results revealed promising anti-tumor activity, including objective responses in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer, during the early stages of PRT3789 monotherapy dose escalation.Additionally, among 26 advanced, heavily pre-treated NSCLC or esophageal cancer patients who were assessable for efficacy, seven exhibited tumor reduction.Currently, Prelude’s stock has fallen by 27.85 percent, trading at $3.48 on the Nasdaq.The material has been provided by InstaForex Company – www.instaforex.com
- France’s HICP Growth Slightly Eases in September: A Year-Over-Year Analysis - October 15, 2024
- France’s Harmonized Consumer Prices Index Dips in September 2024, Marking a Significant Economic Shift - October 15, 2024
- French Inflation Faces Sharp Decline in September: CPI Records -1.3% - October 15, 2024
